Fig. 4: Assessing the potency of neutralizing antibodies. | Nature Communications

Fig. 4: Assessing the potency of neutralizing antibodies.

From: Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies

Fig. 4

a Neutralizing capabilities of FDA EUA-approved therapeutic antibodies Regn10933 (left, casirivimab), Regn10987 (center, imdevimab), and JS016 (right, etesevimab) were evaluated using Neu-SATiN against different S variants. b Evaluation of neutralizing antibodies in individuals with unvaccinated sera (n = 2), with one vaccination dose (n = 4), with two vaccination doses and collected within 50 days after the second shot (n = 13, intervals between shots were 21–37 days), and with two vaccination doses collected more than 50 days after the second shot (n = 5, intervals between shots were 21–36 days). c Aggregated data showing titers at 50% neutralization (NT50) for each group. Source data are provided as a Source data file.

Back to article page